Accentia is the company which bought the rights to high dose cyclophosphamide against the spectrum of autoimmune diseases and named it "Revimmune".
The situation you see looks mixed up from the outside but seems normal for researchers who started collaborating on a project and later go their separate ways, yet continue collaboration on the project.
In searching the internet it seems that Dr Gladstone started at Johns Hopkins (collaborating with HDC) and later went to Stony brook. I thought he was still at Stony brook until you mentioned it and now I notice that his last paper he is listed as being at Hematology Oncology Associates of Western Suffolk http://www.hemoncsuffolk.com/physicians ... one_md.php
In other words, what seems like multiple places working separately with HDC are (seemingly) working together, or at least in association.
J Neuroimmunol. 2007 Sep 11; [Epub ahead of print]Click here to read Links
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Gladstone DE, Golightly MG, Brannagan TH 3rd.
Hematology Oncology Associates of Western Suffolk, 24 East Main Street, Bay Shore, NY 11706, United States.
INTRODUCTION: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. METHOD: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. RESULTS: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. DISCUSSION: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.
PMID: 17854912 [PubMed - as supplied by publisher]